KALV
Kalvista Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.44B
P/E Ratio
—
EPS
$-3.94
Beta
-0.11
52W High
$27.00
52W Low
$9.83
50-Day MA
$24.15
200-Day MA
$16.91
Dividend Yield
—
Profit Margin
-118.70%
Forward P/E
25.45
PEG Ratio
0.00
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $114.48M |
| Gross Profit (TTM) | $58.47M |
| EBITDA | $-138.45M |
| Operating Margin | -57.40% |
| Return on Equity | -190.20% |
| Return on Assets | -61.00% |
| Revenue/Share (TTM) | $2.11 |
| Book Value | $-0.38 |
| Price-to-Book | 49.03 |
| Price-to-Sales (TTM) | 12.56 |
| EV/Revenue | 914.43 |
| EV/EBITDA | -3.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 30.70% |
| Shares Outstanding | $53.24M |
| Float | $38.18M |
| % Insiders | 1.72% |
| % Institutions | 136.55% |
Historical Volatility
HV 10-Day
1.39%
HV 20-Day
1.94%
HV 30-Day
1.90%
HV 60-Day
80.15%
HV Rank
0.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($27.00 target)
1
Buy6
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026